Cat. No.: HY-13470

GSK126

Name: GSK126
Brand: MedChemExpress
SKU: HY-13470
Price: 72.00 USD
Availability: InStock
Rating: 5 (105 reviews)

(Synonyms: GSK2816126A)

105 Cited Publications

Avis client

Based on 105 publication(s) in Google Scholar

GSK126 (GSK2816126A) is a potent, highly selective inhibitor of EZH2 methyltransferase with an IC₅₀ of 9.9 nM.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.75%
CAS No.: 1346574-57-9
Formule: C₃₁H₃₈N₆O₂
Masse moléculaire:526.67

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

GSK126 Chemical Structure

CAS No.: 1346574-57-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (105)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

GSK126 (GSK2816126A) is a potent, highly selective inhibitor of EZH2 methyltransferase with an IC₅₀ of 9.9 nM^[1].

IC₅₀ & Target^[1]

EZH2

9.9 nM (IC₅₀)

Voir tous les produits spécifiques à Isoform Histone Methyltransferase :

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	10.4 μM Compound: GSK126	Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
A2780	IC₅₀	12 μM Compound: GSK126	Antiproliferative activity against human A2780 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
A549	GI₅₀	18.7 μM Compound: GSK-126	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by WST-1 assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by WST-1 assay	[PMID: 24767850]
A549	IC₅₀	23 μM Compound: GSK126	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
A549	IC₅₀	23.65 nM Compound: Chemical probe: GSK126	Antiproliferative activity against human A549 cells harbouring KrasG12D/+ mutant assessed as reduced cell viability treated for 96 hrs in RPMI medium by cell titre blue reagent based assay (Rvb = 32.03 nM) Antiproliferative activity against human A549 cells harbouring KrasG12D/+ mutant assessed as reduced cell viability treated for 96 hrs in RPMI medium by cell titre blue reagent based assay (Rvb = 32.03 nM)	[PMID: 30487290]
A549	IC₅₀	6.9 nM Compound: Chemical probe: GSK126	Antiproliferative activity against human A549 cells harbouring KrasG12D/+ mutant assessed as reduced cell viability treated for 96 hrs in IFN medium by cell titre blue reagent based assay (Rvb = 8.1 nM) Antiproliferative activity against human A549 cells harbouring KrasG12D/+ mutant assessed as reduced cell viability treated for 96 hrs in IFN medium by cell titre blue reagent based assay (Rvb = 8.1 nM)	[PMID: 30487290]
BT-549	IC₅₀	16.27 μM Compound: GSK126	Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
BT-549	IC₅₀	19.19 μM Compound: GSK; GSK126	Cytotoxicity against human BT-549 cells incubated for 72 hrs by MTT assay Cytotoxicity against human BT-549 cells incubated for 72 hrs by MTT assay	[PMID: 38134746]
BT-549	IC₅₀	23.3 μM Compound: GSK126	Antiproliferative activity against human BT-549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human BT-549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
BT-549	IC₅₀	8.28 μM Compound: GSK; GSK126	Synergistic cytotoxicity against human BT-549 cells incubated for 72 hrs in presence of Niraparib by MTT assay Synergistic cytotoxicity against human BT-549 cells incubated for 72 hrs in presence of Niraparib by MTT assay	[PMID: 38134746]
Daudi	GI₅₀	11.2 μM Compound: GSK-126	Cytotoxicity against human Daudi cells assessed as growth inhibition after 72 hrs by WST-1 assay Cytotoxicity against human Daudi cells assessed as growth inhibition after 72 hrs by WST-1 assay	[PMID: 24767850]
ES-2	IC₅₀	32.2 μM Compound: GSK126	Antiproliferative activity against human ES2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human ES2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
HeLa	IC₅₀	0.28 μM Compound: GSK-126	Inhibition of EZH2 in human HeLa cells assessed as reduction in H3K27me3 levels incubated for 72 hrs by ELISA method Inhibition of EZH2 in human HeLa cells assessed as reduction in H3K27me3 levels incubated for 72 hrs by ELISA method	[PMID: 26189078]
HEY	IC₅₀	>100 μM Compound: GSK126	Antiproliferative activity against human HEY cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HEY cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
HK-2	IC₅₀	>40 μM Compound: GSK126	Antiproliferative activity against human HK-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HK-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
HL-60	IC₅₀	14.05 μM Compound: GSK126	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
L02	IC₅₀	>40 μM Compound: GSK126	Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
MCF-10A	IC₅₀	>40 μM Compound: GSK126	Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
MCF-10A	IC₅₀	>40 μM Compound: GSK; GSK126	Cytotoxicity against human MCF-10A cells incubated for 72 hrs by MTT assay Cytotoxicity against human MCF-10A cells incubated for 72 hrs by MTT assay	[PMID: 38134746]
MCF-10A	IC₅₀	>40 μM Compound: GSK; GSK126	Synergistic cytotoxicity against human MCF-10A cells incubated for 72 hrs in presence of Niraparib by MTT assay Synergistic cytotoxicity against human MCF-10A cells incubated for 72 hrs in presence of Niraparib by MTT assay	[PMID: 38134746]
MCF7	IC₅₀	18.8 μM Compound: GSK126	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
MCF7	IC₅₀	21.38 μM Compound: GSK126	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
MDA-MB-231	IC₅₀	12.82 μM Compound: GSK126	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
MDA-MB-231	IC₅₀	13.18 μM Compound: GSK; GSK126	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 38134746]
MDA-MB-231	IC₅₀	6.32 μM Compound: GSK; GSK126	Synergistic cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs in presence of Niraparib by MTT assay Synergistic cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs in presence of Niraparib by MTT assay	[PMID: 38134746]
MDA-MB-468	IC₅₀	11.92 μM Compound: GSK126	Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
Medulloblastoma cell	IC₅₀	4.64 μM Compound: Chemical Probe: GSK126	Antiproliferative activity in Ptch1-deficient mouse medulloblastoma cell after 48 hrs by CCK-8 assay Antiproliferative activity in Ptch1-deficient mouse medulloblastoma cell after 48 hrs by CCK-8 assay	[PMID: 32579914]
MV4-11	IC₅₀	7.34 μM Compound: GSK126	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35623249]
NCI-H1703	IC₅₀	>100 μM Compound: GSK126	Antiproliferative activity against human NCI-H1703 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1703 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
OAW-42	IC₅₀	55.4 μM Compound: GSK126	Antiproliferative activity against human OAW-42 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human OAW-42 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
OVCAR-3	IC₅₀	29.8 μM Compound: GSK126	Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
PA-1	IC₅₀	12.2 μM Compound: GSK126	Antiproliferative activity against human PA-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human PA-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
PC-3	GI₅₀	9.4 μM Compound: GSK-126	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by WST-1 assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by WST-1 assay	[PMID: 24767850]
PC-3	IC₅₀	10.04 μM Compound: 8; GSK126	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell proliferation incubated for 3 to 7 days followed by replacement of medium containing compound every 3 days by CCK8 assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell proliferation incubated for 3 to 7 days followed by replacement of medium containing compound every 3 days by CCK8 assay	[PMID: 35569264]
Pfeiffer	GI₅₀	0.18 μM Compound: GSK-126	Cytotoxicity against human Pfeiffer cells expressing EZH2 A667G mutant assessed as growth inhibition after 72 hrs by WST-1 assay Cytotoxicity against human Pfeiffer cells expressing EZH2 A667G mutant assessed as growth inhibition after 72 hrs by WST-1 assay	[PMID: 24767850]
SK-BR-3	IC₅₀	15.5 μM Compound: GSK126	Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
SK-OV-3	IC₅₀	10.49 μM Compound: 8; GSK126	Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 3 to 7 days followed by replacement of medium containing compound every 3 days by CCK8 assay Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 3 to 7 days followed by replacement of medium containing compound every 3 days by CCK8 assay	[PMID: 35569264]
SK-OV-3	IC₅₀	68.4 μM Compound: GSK126	Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 36692394]
T98G	GI₅₀	12.6 μM Compound: GSK-126	Cytotoxicity against human T98G cells assessed as growth inhibition after 72 hrs by WST-1 assay Cytotoxicity against human T98G cells assessed as growth inhibition after 72 hrs by WST-1 assay	[PMID: 24767850]
U2932	GI₅₀	6.7 μM Compound: GSK-126	Cytotoxicity against human U2932 cells assessed as growth inhibition after 72 hrs by WST-1 assay Cytotoxicity against human U2932 cells assessed as growth inhibition after 72 hrs by WST-1 assay	[PMID: 24767850]
U-87MG ATCC	GI₅₀	28.5 μM Compound: GSK-126	Cytotoxicity against human U87MG cells assessed as growth inhibition after 72 hrs by WST-1 assay Cytotoxicity against human U87MG cells assessed as growth inhibition after 72 hrs by WST-1 assay	[PMID: 24767850]

In Vitro

GSK126 potently inhibits both wild-type and mutant EZH2 methyltransferase activity with similar potencies (K_i=0.5-3 nM) independent of substrate used, and is competitive with S-adenosyl-methionine (SAM) and non-competitive with peptide substrates. GSK126 is highly selective against other methyltransferases and multiple other protein classes (EZH1, IC₅₀=680 nM)^[1]. Treatment of three SCLC cell lines with GSK126, induces growth inhibition. SCLC cell lines (Lu130, H209, and DMS53) are treated with 0.5, 2, and 8 μM GSK126, and growth curve is analyzed by WST-8 assay. Inhibition of cellular growth by GSK126 treatment is observed at 8 μM in all the three cell lines, while Lu130 and H209 are more sensitive to GSK126, even at lower doses^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GSK126 is administered intraperitoneally at a dose volume of 0.2 mL per 20 g body weight in female beige SCID mice. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1346574-57-9
Appearance Solid
Masse moléculaire 526.67
Formule C₃₁H₃₈N₆O₂
Color White to yellow
SMILES

O=C(C1=CC(C2=CC=C(N3CCNCC3)N=C2)=CC4=C1C(C)=CN4[C@@H](C)CC)NCC5=C(C)C=C(C)NC5=O
Synonyms

GSK2816126A
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (105)

All WB

Sort by:

Journal Impact Factor

Cell

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. [Abstract]

2018 Sep 20;175(1):186-199.e19. PMID: 30220457

GSK126 purchased from MedChemExpress. Usage Cited in: Cell. 2018 Sep 20;175(1):186-199.e19. [Abstract]

Cells are treated with EPZ-6438 (1 μM) or GSK126 (1 μM) for 6 days. Protein levels are analyzed by immunoblotting. Cells are treated with EPZ-6438 (1 μM), JQ1 (0.25 μM) alone or combination for 6 days. Protein levels are analyzed by immunoblotting.
Immunity

Succinate preserves CD8+ T cell fitness to augment antitumor immunity. [Abstract]

2025 Aug 9:S1074-7613(25)00326-7. PMID: 40816269
Blood

Non-canonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias. [Abstract]

2022 Dec 1;140(22):2358-2370. PMID: 35984905
Bone Res

JMJD3-driven epigenetic reprogramming of p16INK4a-positive cells promotes tendon regeneration. [Abstract]

2026 Jun 11;14(1):65. PMID: 42276987
Nat Commun

S-nitrosylation of EZH2 alters PRC2 assembly, methyltransferase activity, and EZH2 stability to maintain endothelial homeostasis. [Abstract]

2025 Apr 27;16(1):3953. PMID: 40289112
Nat Commun

Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. [Abstract]

2024 May 21;15(1):4327. PMID: 38773088
Mol Cell

CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. [Abstract]

2023 Dec 7;83(23):4370-4385.e9. PMID: 38016475
Theranostics

PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression. [Abstract]

2021 Jan 27;11(8):3742-3759. PMID: 33664859
Genes Dis

2026 Mar 12.
Acta Pharm Sin B

Deubiquitinase OTUD6A alleviates acetaminophen-induced liver injury by targeting EZH2 to reduce cell death in hepatocytes. [Abstract]

2025 Sep;15(9):4772-4788. PMID: 41049752
J Exp Clin Cancer Res

CircGSK3B promotes RORA expression and suppresses gastric cancer progression through the prevention of EZH2 trans-inhibition. [Abstract]

2021 Oct 19;40(1):330. PMID: 34666800
Sci Adv

BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling. [Abstract]

2025 Apr 25;11(17):eads6385. PMID: 40279411
Cell Death Differ

Ezh2 competes with p53 to license lncRNA Neat1 transcription for inflammasome activation. [Abstract]

2022 Oct;29(10):2009-2023. PMID: 35568718
Carbohydr Polym

Chitosan/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo/immuno-resistance in unresectable metastatic melanoma. [Abstract]

2024 Dec 15:346:122645. PMID: 39245506
Cell Death Dis

Targeting EZH2-driven cholesterol metabolic vulnerability through Napabucasin suppresses ovarian cancer metastasis. [Abstract]

2026 Jun 27;17(1):603. PMID: 42373608
Cell Death Dis

A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis. [Abstract]

2025 Apr 14;16(1):291. PMID: 40229247
Cell Death Dis

Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer. [Abstract]

2022 Aug 29;13(8):748. PMID: 36038549
Cell Death Dis

Tumor-suppressive function of EZH2 is through inhibiting glutaminase. [Abstract]

2021 Oct 20;12(11):975. PMID: 34671029
Cell Death Dis

Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer. [Abstract]

2021 Sep 25;12(10):878. PMID: 34564701
Cell Death Dis

Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. [Abstract]

2018 Jan 26;9(2):129. PMID: 29374157

GSK126 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Jan 26;9(2):129. [Abstract]

The effects of treatment with the indicated epigenetic inhibitors on cleaved PARP (Clv-PARP) expression in both PC9/ER and HCC827/ER cells. β-actin is used as a loading control.
Cancer Lett

Combined inhibition of EZH2 and the autotaxin-LPA-LPA2 axis exerts synergistic antitumor effects on colon cancer cells. [Abstract]

2023 Jul 10:566:216226. PMID: 37230222
Cancer Lett

EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition. [Abstract]

2022 Jan 1:524:151-160. PMID: 34655667
J Exp Med

Macrophage/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3. [Abstract]

2018 May 7;215(5):1365-1382. PMID: 29626115

GSK126 purchased from MedChemExpress. Usage Cited in: J Exp Med. 2018 May 7;215(5):1365-1382. [Abstract]

Immunoblot analysis of Ezh2, H3K27me3, H3, and Hsp60 (loading control) in whole-cell lysates of the indicated proinflammatory genes of macrophages or microglia that are pretreated with DMSO or GSK126 (4 μM) for 3 d and then left nontreated (NT) or stimulated for 6 h with the ligands of different TLRs.
Clin Cancer Res

Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. [Abstract]

2024 Nov 15;30(22):5166-5179. PMID: 39269307
Acta Pharmacol Sin

DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I/MDA5-MAVS to enhance antitumor immunity. [Abstract]

2025 Aug 19. PMID: 40830678
Acta Pharmacol Sin

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. [Abstract]

2022 Feb;43(2):457-469. PMID: 33850273
J Orthop Translat

2026 Jan 22.
J Orthop Translat

Targeting MAT2A synergistically induces DNA damage in osteosarcoma cells through EZH2-mediated H3K27me3 modification. [Abstract]

2025 Oct 16:55:346-359. PMID: 41146859
Sci China Life Sci

Histone modification landscape and the key significance of H3K27me3 in myocardial ischaemia/reperfusion injury. [Abstract]

2023 Jun;66(6):1264-1279. PMID: 36808292
Proc Natl Acad Sci U S A

A PHF19-YTHDC1 condensate switches EZH2-mediated gene suppression to activation for prostate cancer progression. [Abstract]

2025 Oct 28;122(43):e2510386122. PMID: 41129231
Oncogene

BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. [Abstract]

2021 Apr;40(15):2711-2724. PMID: 33712705
Leukemia

A Perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged acute myeloid leukemia. [Abstract]

2026 Mar 25. PMID: 41882099
Int J Biol Macromol

Emodin exerts antitumor effects in cervical cancer cells by reprogramming phospholipid metabolism through modulation of H3K27ac and H3K27me3. [Abstract]

2026 Apr:357:151454. PMID: 41856179
Neural Regen Res

Essential role of MALAT1 in reducing traumatic brain injury. [Abstract]

2022 Aug;17(8):1776-1784. PMID: 35017438
Sens Actuators B Chem

2025 Sep 3;446:138681.
Br J Cancer

Fibroblast growth factor signals drive the metastatic behavior in small cell lung cancer. [Abstract]

2025 Dec 13. PMID: 41390896
Cell Rep

Fibrillarin regulates epithelial integrity via EZH2-mediated modulation of scribble expression. [Abstract]

2025 Nov 25;44(12):116608. PMID: 41296560
Cell Rep

Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. [Abstract]

2021 Jul 20;36(3):109410. PMID: 34289358
Cell Rep

Requisite Chromatin Remodeling for Myeloid and Erythroid Lineage Differentiation from Erythromyeloid Progenitors. [Abstract]

2020 Nov 17;33(7):108395. PMID: 33207205
Cell Rep

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. [Abstract]

2018 Feb 27;22(9):2236-2245. PMID: 29490263
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
J Med Chem

Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. [Abstract]

2024 Sep 12;67(17):15098-15117. PMID: 39145486
J Med Chem

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. [Abstract]

2021 Oct 28;64(20):15170-15188. PMID: 34664960
J Invest Dermatol

EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. [Abstract]

2020 Dec;140(12):2442-2454.e5. PMID: 32360600
Mol Cancer Ther

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. [Abstract]

2024 Oct 1;23(10):1404-1417. PMID: 38894678
JCI Insight

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. [Abstract]

2022 Aug 22;7(16):e155899. PMID: 35852858
Acta Neuropathol Commun

DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma. [Abstract]

2024 Mar 13;12(1):40. PMID: 38481314
Biochem Pharmacol

FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy. [Abstract]

2023 Jun:212:115570. PMID: 37119860
Int Endod J

EZH2 knockout in mice activates STAT3 signalling via STAT3 methylation and modulates ferroptosis in pulpitis-affected dental pulp vascular endothelial cells: A laboratory investigation. [Abstract]

2025 Mar 31. PMID: 40164972
Breast Cancer Res

A hybrid epithelial-mesenchymal transition program enables basal epithelial cells to bypass stress-induced stasis and contributes to a metaplastic breast cancer progenitor state. [Abstract]

2024 Dec 18;26(1):184. PMID: 39696672
Mol Cancer Res

Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM. [Abstract]

2020 Aug;18(8):1142-1152. PMID: 32366675
Clin Epigenetics

Azithromycin attenuates wheezing after pulmonary inflammation through inhibiting histone H3K27me3 hypermethylation mediated by EZH2. [Abstract]

2023 Jan 23;15(1):12. PMID: 36691058
Stem Cell Reports

An innovative in vitro system unveils IGF1R signaling regulating Merkel cell generation. [Abstract]

2025 Dec 26:102756. PMID: 41455470
Am J Physiol Cell Physiol

Elevation of H3K27me3 level contributes to the radioresistance of nasopharyngeal carcinoma by inhibiting OAS1 expression. [Abstract]

2024 Jan 1;326(1):C60-C73. PMID: 38009194
Biochim Biophys Acta Mol Basis Dis

YAP promotes breast cancer metastasis by repressing growth differentiation factor-15. [Abstract]

2018 May;1864(5 Pt A):1744-1753. PMID: 29499325
J Mol Cell Cardiol

EZH2 as a novel therapeutic target for atrial fibrosis and atrial fibrillation. [Abstract]

2019 Oct:135:119-133. PMID: 31408621
Neoplasia

Cholesterol biosynthesis as a drug-induced vulnerability in diffuse large B cell lymphoma insensitive to EZH2 inhibition. [Abstract]

2025 Oct 27:70:101243. PMID: 41151153
Neoplasia

A methyl-to-acetyl switch in H3K27 drives metabolic reprogramming and resistance to BRAFV600E inhibition in melanoma. [Abstract]

2025 Oct:68:101223. PMID: 40850308
Cancers (Basel)

SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters. [Abstract]

2023 Jun 3;15(11):3043. PMID: 37297005
Cancers (Basel)

TPH1 and 5-HT7 Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma. [Abstract]

2021 Oct 22;13(21):5305. PMID: 34771469
Cancers (Basel)

Identification of Androgen Receptor Metabolic Correlome Reveals the Repression of Ceramide Kinase by Androgens. [Abstract]

2021 Aug 26;13(17):4307. PMID: 34503116
Neoplasia

Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma. [Abstract]

2016 Feb;18(2):121-32. PMID: 26936398
iScience

CD2 costimulation strength: A key regulator of T cell function and anti-tumor immunity that is epigenetically regulated. [Abstract]

2025 Nov 10;28(12):113977. PMID: 41377664
Cytotherapy

Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer. [Abstract]

2024 Feb;26(2):136-144. PMID: 38149947
Neurochem Res

Genome-wide Analysis of Histone H3 Lysine 27 Trimethylation Profiles in Sciatic Nerve of Chronic Constriction Injury Rats. [Abstract]

2023 Jun;48(6):1945-1957. PMID: 36763313
FASEB J

LncRNA CASC15-EZH2 Interaction Promotes Ischemia-Reperfusion Induced Acute Kidney Injury via Regulating SALL1 and Wnt/β-Catenin Pathway. [Abstract]

2026 Jun 15;40(11):e71989. PMID: 42217179
FASEB J

H3K27me3 Modified FBXO10 Promotes Golgi Stress to Accelerate Traumatic Brain Injury via Activation of the RAS/ERK Axis. [Abstract]

2026 Apr 30;40(8):e71791. PMID: 41999223
FEBS J

Reprogramming of histone methylation controls the differentiation of monocytes into macrophages. [Abstract]

2017 May;284(9):1309-1323. PMID: 28304152
J Biol Chem

A Novel Role of Chromodomain Protein CBX8 in DNA Damage Response. [Abstract]

2016 Oct 28;291(44):22881-22893. PMID: 27555324
Reg Anesth Pain Med

Role of spinal Barrier-to-Autointegration Factor (BAF) in the epigenetic silencing of the mu-opioid receptor gene in neuropathic pain. [Abstract]

2025 Feb 6:rapm-2024-106004. PMID: 39915245
Cell Cycle

Sustained activation of NF-κB through constitutively active IKKβ leads to senescence bypass in murine dermal fibroblasts. [Abstract]

2024 Feb;23(3):308-327. PMID: 38461418
Vet Res

EZH2 enhances PCV2 replication through inhibition of MMP1 and MMP12 transcription activity. [Abstract]

2026 Jun 8;57(1):101. PMID: 42260657
J Transl Autoimmun

A novel epigenetic regulation of JAM-A by EZH2-DNMT3A cascade contributes to T cell adhesion via the activation of Rap1a in lupus patients. [Abstract]

2026 Feb 25:12:100362. PMID: 41815940
Br J Haematol

The mechanism of EZH2/H3K27me3 downregulating CXCL10 to affect CD8+ T cell exhaustion to participate in the transformation from myelodysplastic syndrome to acute myeloid leukaemia. [Abstract]

2025 Apr 9. PMID: 40201935
Exp Cell Res

Metastatic breast cancer cells adapt to a soft environment with limited involvement of mechanotransduction. [Abstract]

2025 Jun 2;450(2):114629. PMID: 40466802
J Cancer

EZH2 Exacerbates Breast Cancer by Methylating and Activating STAT3 Directly. [Abstract]

2021 Jun 26;12(17):5220-5230. PMID: 34335938
Exp Eye Res

Hypoxia-driven histone modification landscape and the role of EZH2 in retinal neovascularization. [Abstract]

2025 Sep 26:110670. PMID: 41016422
Epigenomics

EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines. [Abstract]

2025 Feb;17(3):145-154. PMID: 39878501
BMC Cardiovasc Disord

Calcineurin/NFATc3 pathway mediates myocardial fibrosis in diabetes by impairing enhancer of zeste homolog 2 of cardiac fibroblasts. [Abstract]

2023 Sep 21;23(1):474. PMID: 37735624
Genes (Basel)

Activation of Steroidogenesis, Anti-Apoptotic Activity, and Proliferation in Porcine Granulosa Cells by RUNX1 Is Negatively Regulated by H3K27me3 Transcriptional Repression. [Abstract]

2020 Apr 30;11(5):495. PMID: 32365901
Technol Cancer Res Treat

Cancer-Associated Fibroblasts Promote Angiogenesis of Hepatocellular Carcinoma by VEGF-Mediated EZH2/VASH1 Pathway. [Abstract]

Jan-Dec 2019;18:1533033819879905. PMID: 31757187
Biochem Cell Biol

GSK126 an Inhibitor of Epigenetic Regulator EZH2 Suppresses Cardiac Fibrosis by Regulating EZH2-PAX6-CXCL10 Pathway. [Abstract]

2023 Feb 1;101(1):87-100. PMID: 36469862
Biomed Res

Constant cGAS activation blunts STING signaling in DU145 prostate cancer cell line. [Abstract]

2026;47(3):89-101. PMID: 42178241
The University of North Dakota

2026.
bioRxiv

2025 Aug 12.
Res Sq

2025 Jul 08.
bioRxiv

AI-assisted Drug Re-purposing for Human Liver Fibrosis. [Abstract]

2025 May 4:2025.04.29.651320. PMID: 40654780
bioRxiv

2025 February 12.
Patent

US20240252638A1.
Patent

US20240350508A1.
bioRxiv

2024 September 11.
Res Sq

2024 May 29.
SSRN

2024 Mar 20.
McGill University

2023 Jul.
bioRxiv

2023 Nov 9.
University of Kentucky

2023 Aug 20.
Research Square Preprint

2023 Jul 21.
bioRxiv

EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas. [Abstract]

2023 Jun 8:2023.06.06.543919. PMID: 37333199
Research Square Print

2022 May.
Biomed Pharmacother

Covalent inhibitors of EZH2: Design, synthesis and evaluation. [Abstract]

2022 Mar:147:112617. PMID: 34998031
bioRxiv

2021 Jan 13.
Research Square Preprint

2020 Jul.
University of California

2020 Feb.
Patent

US20180263995A1.
Oncotarget

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. [Abstract]

2015 Sep 29;6(29):27023-36. PMID: 26304929

GSK126 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2015 Sep 29;6(29):27023-36. [Abstract]

This includes ATF3 (Activating Transcription Factor 3) and metastasis suppressor NDRG1 (N-Myc Downstream Regulated Gene 1) that also shows an upregulation in protein expression (phosphorylated at threonine 346) with GSK126 in two EZH2 mutant cell lines by western blot.

Solvant et solubilité

In Vitro:

DMSO : 12.5 mg/mL (23.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8987 mL

9.4936 mL

18.9872 mL

5 mM

0.3797 mL

1.8987 mL

3.7974 mL

10 mM

0.1899 mL

0.9494 mL

1.8987 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (2.37 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.25 mg/mL (2.37 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (2.37 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.82 mg/mL (1.56 mM); Clear solution

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (18.99 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 1% CMC/0.5% Tween-80 in Saline water

Solubility: 10 mg/mL (18.99 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Kinase Assay^[1]

The five-member PRC2 complex (Flag-EZH2, EED, SUZ12, AEBP2, RbAp48) containing either wild-type or mutant (A677G, Y641N, Y641C, Y641H, Y641S or Y641F) EZH2 is prepared. GSK126 is dissolved in DMSO and tested at concentrations of 0.6 nM to 300 nM with a final DMSO concentration of 2.5%. In contrast to wild-type EZH2 which prefers H3K27me0 as a substrate in vitro, EZH2 Y641 mutants prefer H3K27me2 and have little activity with H3K27me0 or H3K27me1. The A677G mutant is distinct from both the wild-type and Y641 mutant forms of EZH2 in that it efficiently methylates H3K27me0, H3K27me1, and H3K27me2; therefore, histone H3 peptides (residues 21-44; 10 μM final) with either K27me0 (wild type, A677G EZH2), K27me1 (A677G EZH2), or K27me2 (A677G, Y641N, Y641C, Y641H, Y641S and Y641F EZH2) are used as methyltransferase substrates. GSK126 is added to plates followed by addition of 6 nM EZH2 complex and peptide. As the potency of GSK126 is at or near the tight binding limit of an assay run at [SAM]=K_m, _IC50 values are measured at a high concentration of the competitive substrate SAM relative to its K_m (7.5 μM SAM where the SAM K_m is 0.3 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

JUB- and PTRF-introduced DMS53 cells are seeded at density of 1×10³ cells/well in 96-well plate, and cellular growth is analyzed using WST-8 kit at 12, 36, 60, and 84 h. Cellular growth of Lu130, H209, and DMS53 with treatment by DZNep or GSK126 is also analyzed using WST-8 kit. DZNep is dissolved in PBS at 5 mM, and cells are cultured at the final concentration of 5 μM. GSK126 is dissolved in DMSO at 10 mM, and cells are cultured at 0.5, 2, and 8 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
GSK126 or vehicle is administered intraperitoneally at a dose volume of 0.2 mL per 20 g body weight. Pfeiffer or KARPAS-422 cells (1×10⁷) in 100% Matrigel are implanted subcutaneously in female beige SCID mice. Tumors are measured with calipers, and block randomized according to tumour size into treatment groups. For efficacy studies, 10 mice are randomized in each treatment group before the initiation of dosing and GSK126 treatment is initiated once the tumour volumes are approximately 200 mm³ in the Pfeiffer and KARPAS-422 studies and 500 mm³ in the KARPAS-422 intermittent dosing study. Mice are weighed and tumors measured with calipers twice weekly. Two-tailed t-tests are conducted assuming two samples of equal variance.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (284 KB)
SDS (538 KB)
- English - EN (538 KB)
- Français - FR (538 KB)
- Deutsch - DE (538 KB)
- Norwegian - NO (538 KB)
- Español - ES (538 KB)
- Swedish - SV (538 KB)
- Italian - IT (538 KB)
- Korean - KR (538 KB)
- Portuguese - PT (538 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. McCabe MT, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012 Dec 6;492(7427):108-12. [Content Brief]

[2]. Sato T, et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep. 2013 May 29;3:1911. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8987 mL	9.4936 mL	18.9872 mL	47.4681 mL
	5 mM	0.3797 mL	1.8987 mL	3.7974 mL	9.4936 mL
	10 mM	0.1899 mL	0.9494 mL	1.8987 mL	4.7468 mL
	15 mM	0.1266 mL	0.6329 mL	1.2658 mL	3.1645 mL
	20 mM	0.0949 mL	0.4747 mL	0.9494 mL	2.3734 mL

Bioz

Keywords

GSK126

105 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

GSK126

Tazemetostat

GSK343

Decitabine

UNC1999

EI1

Vorinostat

Laduviglusib

Pinometostat

Valemetostat

Trichostatin A

5-Azacytidine

BIX-01294

Publications Citing Use of MedChemExpress (MCE) GSK126

Voir tous les produits spécifiques à Isoform Histone Methyltransferase

Activité biologique

Chemical Information

Publications (105)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

GSK126

Tazemetostat

GSK343

Decitabine

UNC1999

EI1

Vorinostat

Laduviglusib

Pinometostat

Valemetostat

Trichostatin A

5-Azacytidine

BIX-01294

Publications Citing Use of MedChemExpress (MCE) GSK126

Voir tous les produits spécifiques à Isoform Histone Methyltransferase

Activité biologique

Chemical Information

Publications (105)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

GSK126 Related Classifications

HY-13470 Related Classifications

Bioz